Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016. - Wikidata - awgldk - TriplyDB

Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016.

Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016.

http://www.wikidata.org/entity/Q38807878

about

Nanoparticle-Enabled Transdermal Drug Delivery Systems for Enhanced Dose Control and Tissue Targeting One-year safety and efficacy study of bilastine treatment in Japanese patients with chronic spontaneous urticaria or pruritus associated with skin diseases Dupilumab in the treatment of moderate-to-severe atopic dermatitis.Use of systemic corticosteroids for atopic dermatitis: International Eczema Council consensus statement."Inflammatory skin march" in atopic dermatitis and psoriasis.Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis.The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus.Quality assessment of atopic dermatitis clinical practice guidelines in ≤ 18 years.Topical E6005/RVT-501, a novel phosphodiesterase 4 inhibitor, for the treatment of atopic dermatitis.Superiority of a vitamin B12-barrier cream compared with standard glycerol-petrolatum-based emollient cream in the treatment of atopic dermatitis: A randomized, left-to-right comparative trial.Mechanistic insights into topical tacrolimus for the treatment of atopic dermatitis.Antipruritic Effect of Acupuncture in Patients with Atopic Dermatitis: Feasibility Study Protocol for a Randomised, Sham-Controlled Trial.Tacrolimus nanoparticles based on chitosan combined with nicotinamide: enhancing percutaneous delivery and treatment efficacy for atopic dermatitis and reducing dose.Safety and Efficacy of Phototherapy in the Management of Eczema.Guidelines for the management of atopic dermatitis (eczema) for pharmacists.Efficacy and safety of topical JTE-052, a Janus kinase inhibitor, in Japanese adult patients with moderate-to-severe atopic dermatitis: a phase II, multicentre, randomized, vehicle-controlled clinical study.Phase 1 studies to assess the safety, tolerability and pharmacokinetics of JTE-052 (a novel Janus kinase inhibitor) ointment in Japanese healthy volunteers and patients with atopic dermatitis.A clinician's reference guide for the management of atopic dermatitis in Asians

P2860

Q28079462-A64E3082-B25E-4A20-864E-1F0E52413AD3 Q33625914-0F053A3E-AD3E-4D08-96BC-7D938C93CFDA Q39122316-78A24630-20CB-42C4-A6E2-086E796CF2BF Q39150394-4409725C-0748-446A-9428-28BE0D391B61 Q39377564-699E00FC-1784-4AAA-8FF8-5007AA3C43D1 Q39410617-61DC6AE7-B72D-4D2F-92D5-00843D401F4E Q47144191-AFB87EC9-0337-4F8D-84DF-DB757CBFC62F Q47845620-E707F28D-87CE-4A42-AA48-AA5617332621 Q47877796-7A96A06C-E1EE-4469-AA2C-DFB4E4C6C2FB Q48177251-E057539D-0CF8-4819-81E5-D6F4ACD8337B Q48179750-C5FDA6D3-A046-4715-92F7-63B5FC33BC68 Q48189612-AFADD3F9-FD67-4127-82AA-BC1359743E1E Q49165535-6F5C3642-E3CE-493D-9E13-96A6493CF6A9 Q50074873-99FFBEE3-D47C-4F4E-8B82-FF5B3458BA28 Q50144719-972F90CB-260F-4A05-8111-B04ECAFF2362 Q50272808-2728A838-A800-473E-B395-3012CD75036A Q52582955-91615EE4-2F10-4655-AF32-0E2FB3F02D31 Q58596064-03CD26C7-922B-4DEC-A0D5-0DADC55CBE7F

P2860

Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016.

http://www.wikidata.org/entity/Q38807878

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016.

@en

type

label

Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016.

@en

prefLabel

Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016.

@en

P1433

Q38807878-3F02648D-93DA-4482-B478-A5EC2155FADB

P1476

Q38807878-7F76E7B1-EAA9-4A8E-A332-E1B63E74DF8E

P2093

Q38807878-3AE95409-7F67-4612-B215-BF9C7DB97DDE

Q38807878-47C57DF0-731E-40DB-B9AC-16223E67B953

Q38807878-7B8A1B32-F38A-4A64-A477-51FA5C08F5EF

Q38807878-9111634C-24BA-4C80-B309-CD578BA9D04D

Q38807878-A11E264E-96C9-4464-9D0F-73B68AA27209

Q38807878-CCA6556F-B1BB-48F9-B6A3-4DA4632DBDBA

Q38807878-D20EACB4-6D0F-47BA-8149-0392B60C3C40

Q38807878-E493EB7F-67A3-49CF-9E06-FEEA6D64CB30

Q38807878-EAC6EC41-CF53-469F-B15D-D0F6D5ED0CB8

Q38807878-F8940A1F-2C87-4F5E-96F1-6A546DC6A35B

P2860

Q38807878-03C7854C-41C7-45E2-B17E-89E948F1A266

Q38807878-0704DDDA-B71B-4BE0-AC21-E75859EF47DD

Q38807878-0BE6B663-8045-4646-8097-1CB99934B924

Q38807878-0F5848E5-5A52-4497-8BDF-AE8F3B1ED452

Q38807878-14FE475C-EE45-418A-9EFD-E3934AE93F76

Q38807878-15747BC0-5676-4647-96B3-2087FE327EE7

Q38807878-193EC3B7-D58B-49E2-9302-F56E0479EADF

Q38807878-19CE5952-C95F-4DFD-9237-52617E2F49E6

Q38807878-1A7327D1-BFA8-473E-9E34-0E8F8342AC67

Q38807878-1AE8822F-AF4E-4036-8CE7-232AB7985794

P304

Q38807878-1B698E47-F175-4D17-8669-BE6044FD3352

P31

Q38807878-C86E5181-49A2-47C8-A810-A916FBD71E0C

P356

Q38807878-2443FF27-A1DB-41A6-8F98-8C2856147DAD

P433

Q38807878-2372238C-3C19-4FC0-87DB-B36311950B92

P478

Q38807878-D13DAFBF-6DEF-439A-9EB4-B1B063724A16

P50

Q38807878-2BE26FFF-6882-49E1-AC79-7759BFA739EB

P577

Q38807878-1410ECD3-AAC9-4F39-9E7C-11285BDD7FA7

P698

Q38807878-58C14BA2-C9DA-4AE6-B2D5-E72ABD4D2E60

P356

1346-8138.13392

P1433

The Journal of Dermatology

P1476

Clinical Practice Guidelines for the Management of Atopic Dermatitis 2016

@en

P2093

Akio Tanaka

http://www.w3.org/2001/XMLSchema#string

Committee for Clinical Practic ...... ese Dermatological Association

http://www.w3.org/2001/XMLSchema#string

Hidehisa Saeki

http://www.w3.org/2001/XMLSchema#string

Hiroyuki Murota

http://www.w3.org/2001/XMLSchema#string

Makoto Sugaya

http://www.w3.org/2001/XMLSchema#string

Michiko Aihara

http://www.w3.org/2001/XMLSchema#string

Norito Katoh

http://www.w3.org/2001/XMLSchema#string

Takafumi Etoh

http://www.w3.org/2001/XMLSchema#string

Takeshi Nakahara

http://www.w3.org/2001/XMLSchema#string

Tamotsu Ebihara

http://www.w3.org/2001/XMLSchema#string

P2860

Reduced secretory antibody response to live attenuated measles and poliovirus vaccines in malnourished children

Probiotics in primary prevention of atopic disease: a randomised placebo-controlled trial

Thymus and activation regulated chemokine (TARC)/CCL17 and skin diseases

Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice

Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis

Clinical and cost-effectiveness of once-daily versus more frequent use of same potency topical corticosteroids for atopic eczema: a systematic review and economic evaluation

Common loss-of-function variants of the epidermal barrier protein filaggrin are a major predisposing factor for atopic dermatitis

Efficacy and safety of hydrocortisone buteprate 0.1% cream in patients with atopic dermatitis

A systematic review of the associations between dose regimens and medication compliance.

Efficacy and tolerability of topical pimecrolimus and tacrolimus in the treatment of atopic dermatitis: meta-analysis of randomised controlled trials.

P304

1117-1145

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1111/1346-8138.13392

http://www.w3.org/2001/XMLSchema#string

P433

10

http://www.w3.org/2001/XMLSchema#string

P478

43

http://www.w3.org/2001/XMLSchema#string

P50

Kenji Kabashima

P577

2016-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27076388

http://www.w3.org/2001/XMLSchema#string